Lifeboat Foundation

The transhumanist vision of a transformed and technologically enhanced humanity is no longer a science fiction pipe dream. The technological and scientific breakthroughs our society has experienced over the past couple of decades perhaps stand testament to that.

Applied science has certainly come a long way too, but we are yet to crack the brain’s enigma code. How would humanity benefit if we were to crack it? Neuroprosthetics seem to be a window into the future.

Can brain activity be translated into movement?

Continue reading “Scientists have found a way to translate brain activity into movement” »

http://www.blogtalkradio.com/aquarianradio/2017/12/29/ira-s-…et-theresa

Read more

Scientists, who had previously cloned polo ponies, have achieved yet another breakthrough in their work that could lead to the creation of genetically engineered “super-horses” that are faster, stronger and better jumpers than regular horses within two years.

Scientists in Argentina reportedly managed to rewrite the genomes of cloned horses by using a powerful DNA editing technique called CRISPR. They also produced healthy embryos that are now expected to be implanted into a surrogate mother by 2019.

CRISPR, an acronym that stands for Clustered, Regularly Interspaced, Short Palindromic Repeats, is basically a technique in a bacteria’s immune system. When a virus invades a bacterial cell, the CRISPR system captures a piece of the virus’s DNA and slides it into a section of the bacteria’s own DNA, allowing it to detect and destroy the virus as well as similar viruses in future attacks.

Continue reading “Faster, stronger, better jumpers: Genetically engineered ‘super-horses’ to be born in 2019” »

China has unveiled three-year plans to increase the country’s economic competitiveness by developing “key technologies” in nine industrial sectors, from robotics to railways.

Other areas include smart cars, robotics, advanced shipbuilding and maritime equipment, modern agricultural machinery, advanced medical devices and drugs, new materials, smart manufacturing and machine tools.

The aim is “to make China a powerful manufacturing country” and upgrade the nation’s industrial power through “the internet, big data and artificial intelligence”, the commission said.

Continue reading “China’s latest plans to dominate robot, smart car and railway industries by 2020” »

With only a few days left of 2017 we are $1,206,000 towards our $1,250,000 Winter Fundraiser goal.

Please help us reach our $1,250,000 goal by donating generously today! Remember, your support is crucial to our continued fight against age-related diseases.

Visit: http://www.sens.org/donate

Continue reading “We are almost to our final goal!” »

TOKYO — Japan’s Otsuka Pharmaceutical plans to roll out the world’s first commercial “digital pill” in the U.S. as early as next spring. The U.S. Food and Drug Administration in November green-lighted the drugmaker to produce and sell the product, Abilify MyCite.

The end of the year is approaching, and as we prepare for the celebrations for the new year, what could be better than sitting down with a warm drink and recapping 2017 in the world of rejuvenation biotechnology?

Winter kick-off

Continue reading “Looking Back at 2017: A Year in Rejuvenation Biotechnology” »

Usually, when we’ve referred to Crispr, we’ve really meant Crispr/Cas9—a riboprotein complex composed of a short strand of RNA and an efficient DNA-cutting enzyme. It did for biology and medicine what the Model T did for manufacturing and transportation; democratizing access to a revolutionary technology and disrupting the status quo in the process. Crispr has already been used to treat cancer in humans, and it could be in clinical trials to cure genetic diseases like sickle cell anemia and beta thalassemia as soon as next year.

But like the Model T, Crispr Classic is somewhat clunky, unreliable, and a bit dangerous. It can’t bind to just any place in the genome. It sometimes cuts in the wrong places. And it has no off-switch. If the Model T was prone to overheating, Crispr Classic is prone to overeating.

Even with these limitations, Crispr Classic will continue to be a workhorse for science in 2018 and beyond. But this year, newer, flashier gene editing tools began rolling off the production line, promising to outshine their first-generation cousin. So if you were just getting your head around Crispr, buckle up. Because gene-editing 2.0 is here.